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Objectives: To formulate and characterize miglitol
(MGL)-loaded microspheres as a drug delivery system for
oral administration to prolong the duration of action for
achieving reductions of multiple doses. MGL, an oral
antihyperglycaemic agent, possesses a short elimination
half-life of 2 h, so itmust be administered inmultiple doses.
Methods: A 32 full factorial design was employed for
microsphere formulation using the solvent evaporation
technique. The influences of two independent variables,
the polymer and surfactant concentrations, on dependent
variables, such as drug loading (DL) and the encapsula-
tion efficiency (EE), were statistically investigated using
Design Expert Software. Microspheres were character-
ized using field emission scanning electron microscopy
(FE-SEM), Fourier transform infrared spectrophotom-
etry (FTIR), and X-ray diffraction (XRD) and were
evaluated for their in vitro drug release and stability at
accelerated conditions.
Results: The statistical evaluation of the design showed
quadratic and linear models as significant models for DL
(R2: 0.9932) and EE (R2 0.9696). The sizes of particles
ranged from 54.7 mm to 140 mm, and the particles were
spherical in shape with coarse surfaces. The most signif-
icant factor was the polymer amount. FTIR and XRD
studies confirmed the drug-polymer compatibility.
In vitro release of MGL from polymeric microspheres was
found to occur a slower rate of up to 10 h.
Conclusion: The developed poly-e-caprolactone-loaded
MGL microspheres can be successfully formulated.
These microspheres can provide a promising sustained
release drug delivery system for the treatment of hyper-
glycaemia associated with type-2 diabetes mellitus.y. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2016.03.006
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Diabetes mellitus is a chronic disease that is increasing at
an alarming rate around the world. Individuals with type-2
diabetes are increasing in number in every country; the
disease affects major body systems, leading to serious
problems such as kidney failure, lower limb amputation,
heart disease, and stroke, and it is the seventh leading cause
of death.1,2 a-Glucosidase inhibitors can decrease
postprandial plasma blood glucose levels by blocking
oligosaccharide catabolism.3,4
Miglitol (MGL) is an a-glucosidase inhibitor used as oral
antihyperglycaemic agent, and it is indicated for the treat-
ment of patients with type-2 diabetes mellitus.5 Chemically, it
is (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)
piperidine-3,4,5-triol. The dose is 25, 50 or 100 mg twice
daily.6,7 Several clinical studies have reported that MGL as
monotherapy and in combination with other antidiabetic
drugs is effective and ultimately reduces cardiovascular risk
in cases of metabolic syndrome,8,9,10e11 and doses of these
agents can be adjusted accordingly.12 The majority of
adverse effects associated with MGL treatment involve
disturbances of the gastrointestinal tract. Additionally,
MGL has been reported to have a short elimination half-
life (2 h),13 requiring that it be administered in multiple
doses daily; thus, there is an immense need to design and
formulate new drug delivery systems that would effectively
sustain the release of MGL, which would help to reduce
the dosing frequency and adverse effects.
Various techniques have been reported for microsphere
preparation; solvent evaporation techniques are very popu-
lar in the pharmaceutical industry due to their simplicity and
cost-effectiveness. Microspheres can be effectively utilized as
sustained drug delivery systems, ensuring drug release by
maintaining therapeutic concentrations for prolonged
periods of time.14e17
Poly-e-caprolactone (PCL), a biodegradable and
biocompatible polymer, is ideally suitable for the controlled
release of encapsulated drug over the long term.18,19 PCL is
relatively hydrophobic and does not swell significantly in
aqueous medium, but its degradation includes a bulk
erosion mechanism. Due to its in vitro stability, it has been
used in sustained drug delivery applications.20,21
Response surface methodology (RSM) is a statistical and
mathematical technique that has proved more advantageous
than conventional experiments due to its minimum number
of experimental runs.22e24 However, no studies have been
reported for the preparation of MGL microspheres using
PCL applying a statistical design approach.Our aim was to prepare sustained release MGL
microspheres as a potential oral drug delivery system.
Miglitol, a hydrophilic drug, was encapsulated using poly-
e-caprolactone (PCL) polymer. Microspheres were formu-
lated by applying 2 factors (polymer and surfactant
amounts) at 3 levels (1, 0, þ1) to investigate their effects on
drug loading and encapsulation efficiency. The microspheres
were characterized for particle size, surface morphology,
drug loading, encapsulation efficiency, and in vitro release
behaviour.
Materials and Methods
Miglitol was provided by Glenmark Pharmaceuticals
(Nashik, India) as a gift sample; poly-e-caprolactone
(Mn z 70,000e90,000 g/mol) and polyvinyl alcohol (PVA;
Mnz 125,000) were purchased from SigmaeAldrich (USA)
and Thomas Baker (Mumbai, India). Dichloromethane
(DCM) was procured from Merck Specialties Private
Limited (Mumbai, India). All of the other solvents and re-
agents in this work were of analytical/HPLC grade and were
used as provided.
Factorial design
The design of experiment (DOE) extracted the maximum
amount of information in a minimum number experimental
runs. For the assessment and control of critical parameters,
DOE is considered the most powerful technique.25
Various preliminary trials were conducted in accordance
with varying drug, polymer and surfactant concentrations.
Experimentally, the concentrations of PCL and PVA that
yielded microspheres with optimum drug loading, encapsu-
lation efficiency and in vitro release profiles were selected for
the preparation of drug-loaded microspheres. The selected
levels of PCL and PVAwere used to generate a 32 full factorial
(2-factor and 3-level) screening design, and 9 experimental
runs were constructed using Design-Expert Software. In the
present study, the amount of polymer (X1) and the amount of
surfactant (X2) were selected as independent variables (1,
0, þ1 levels) as shown in Table 1. The dependent variables
were drug loading (Y1) and encapsulation efficiency (Y2).
RSM was used to determine statistically the effects of the
variables X1 and X2 on selected variables. Using this
screening design, different models (linear, cross-product
contribution [2FI] and quadratic and cubic model) were
generated, and the significance of the model was determined
by statistical parameters. Two-dimensional (2D) and three-
dimensional (3D) response plots were constructed to study
the main and interaction effects between factors and
responses.
Preparation of MGL-PCL microspheres
MGL-PCL microspheres were prepared by the water-in-
oil-in-water (W1/O/W2) double emulsion solvent evapora-
tion technique.26 Briefly, the drug (100 mg), predissolved in
2 ml of distilled water as an internal aqueous phase (W1),
was emulsified in a 10 ml solution of dichloromethane
Table 1: Composition of miglitol microspheres per 32 full
factorial design.
Coded values Actual values
X1 X2
1 (low level) 600 0.5
0 (middle level) 750 0.7
þ1 (high level) 900 0.9
Formulation batch Independent
variable
Dependent
variable
X1 X2 Y1 Y2
F1 0 þ1 13.28 61.83
F2 1 1 9.59 49.11
F3 0 1 10.71 61.50
F4 0 0 12.35 66.37
F5 þ1 1 16 78.62
F6 þ1 0 17.94 85.12
F7 1 0 8.64 48.23
F8 1 þ1 10.3 50.80
F9 þ1 þ1 20.8 80.17
X1 is the amount of polymer PCL (mg); X2 is the PVA
(surfactant) concentration (% w/v); Y1, Y2 are dependent
variables: drug loading (%) and encapsulation efficiency (%),
respectively.
Poly-e-caprolactone loaded miglitol microspheres366(DCM) containing PCL polymer as an oil phase (O) with
magnetic stirring at 1200 rpm for 10e15 min, resulting in
the primary W1/O emulsion. The amount of drug was
constant throughout all of the experimental runs. Variable
concentrations of PCL-polymer and PVA-surfactant (1,
0, þ1) were used per the screening design for all of the
experimental runs. The primary (W1/O) emulsion was then
injected using a glass syringe with a 21.5 G needle into a
100 ml aqueous PVA (surfactant/emulsifier) solution as an
external aqueous phase (W2) to produce a W1/O/W2 double
emulsion at a speed of 700 rpm at room temperature, using a
four blade stirrer (Remi Elektrotechnik Limited, India).
After complete addition of W1/O primary emulsion to the
external aqueous phase W2, n-hexane was added for hard-
ening of the microspheres. Stirring was continued for 2 h at
the same speed for the purpose of complete evaporation of
dichloromethane-retaining solid microspheres. The resultant
microspheres were collected by vacuum filtration and were
rinsed twice with n-hexane. The filtered microspheres were
allowed to air dry for 24 h and were utilized for further
evaluation.
Characterization of microspheres
Microsphere yield (%)
Themicrosphere yield of all of the batches was determined
using the following equation:% Yield ¼ Practical weight of microspheres
Total weight of ðdrugþ polymerÞ in microsphere pDrug encapsulation efficiency (% EE) and drug loading(% DL)
The amounts of MGL in biodegradable microspheres for
all of the formulations were determined by a reverse-phase
(RP) HPLC system. HPLC analysis with isocratic elution
was performed on an ACME 9000 (SP-930D, Younglin
Instruments, Republic of Korea) assembled with a UV de-
tector (YLUV-730D) using an end capped C-18 column
(Kromasil, 4.6 mm i.d., 250 mm long, 5-mm particle size,
Interchim, France), with water as the mobile phase at a flow
rate of 1 ml/min. The run time required to elute MGL iso-
cratically was 8 min. Briefly, accurately weighed quantities of
microspheres, equivalent to 10 mg ofMGL, were dissolved in
20 ml of diluent (acetonitrile:water e 50:50 [first 10 ml of
acetonitrile were added to dissolve the polymer by sonicat-
ion, and then 10 ml of water were added to ensure precipi-
tation of the polymer]), and the supernatant was filtered
through a 0.45 mm PVDF (polyvinyl difluoride) filter. The
solution was injected through a rheodyne injector with a loop
of 20 ml at room temperature. The detection wavelength was
set at 218 nm. Data acquisition and peak areas were deter-
mined with Younglin Autochro-3000 software. The MGL
calibration curve was linear from 1 to 100 mg/ml (r ¼ 0.989)
and was used to determine content of MGL.
The drug encapsulation efficiency (% EE) and drug
loading (%) of the blend microspheres were calculated using
the following equations:
% EE ¼ Amount of drug in microspheres
Amount of drug used in formulation
 100 (ii)
% DL ¼ Amount of drug determined
Amount of microspheres
 100 (iii)Fourier transform infrared spectrophotometer (FTIR) study
FTIR spectra of pure drug, polymer and drug-loaded
microspheres were determined by the KBr-pellet method
using FTIR (PerkineElmer, FTIR Spectrum-Two, Wal-
tham, USA). The pellets were prepared in a KBr disk by
taking samples in KBr quantities with a ratio of 1:10. These
pellets were scanned in the range of 4000 to 400 cm1.Field emission scanning electron microscopy (FE-SEM)
The surface morphology (shape, size and surface char-
acteristics) of the microspheres was examined by field emis-
sion scanning electron microscopy (Hitachi, Model-S4800).
To view the images, a sample was mounted on a metal stub
using double-sided adhesive tape and was coated with gold
for 80 s and then was placed into the specimen chamber. Thereparation
 100 (i)
M.R. Waghulde and J.B. Naik 367SEM was operated at a distance of 8.2e8.5 mm and an
accelerating voltage of 15.0 kV.
Powder X-ray diffraction (XRD) study
To verify the physical state (crystalline or amorphous) of
the MGL in the microspheres, XRD patterns of pure MGL,
PCL polymer and MGL-loaded microspheres were obtained
by an X-ray diffractometer (Bruker, D-8 Advance) with a
scintillation detector. The studies were performed by
exposing samples to CuK2a rays (a ¼ 1.54060 A˚) with a
voltage of 40 kV and 40 mA of current on a flat plate with q/
2q geometry, where 2q ranged from 5 to 80, with a step
width of 0.03 and a scan time of 0.5 s per step.
In vitro drug release and kinetics
The dried microspheres were evaluated for in vitro drug
release in studies using an eight station dissolution test
apparatus (USP Type II, Eletrolab, Mumbai, India). Accu-
rately weighed, MGL-loaded microspheres equivalent to
10 mg of MGL were introduced into the dissolution bowl
initially for 2 h in acidic medium (0.1 NHCl, volume 900 ml),
followed by fresh phosphate buffer (pH 7.4, volume 900 ml)
for a further duration at a speed of 50 rpm. The temperature
of the dissolution medium was maintained at 37  0.5 C.
Samples of approximately 5 ml were withdrawn from each
bowl at 1e10 h (total of 10 intervals), replenished with the
same volume of fresh dissolution medium to maintain the
sink condition. The samples were filtered through 0.45 mm
PVDF filter and were analysed using a reverse-phase (RP)
HPLC system under chromatographic conditions similar to
those used for the determination of % EE. The amount of
MGL released at each time interval was estimated from the
calibration curve. The marketed formulation of MGL
(Misobit50) was also analysed for its in vitro release and was
compared with the prepared microspheres. The obtained
cumulative drug release data are represented in Table 2 and
were fitted into different kinetic models for quantitative
interpretation. Models such as zero order, first order,
Higuchi model and KorsmeyerePeppas are often used to
describe drug release mechanisms. The criteria to choose
the most suitable kinetic model for drug release of miglitol
from microspheres was based on the highest R2 value
(coefficient of determination).22 The experimental runs
were conducted in triplicate for each formulation.Table 2: Batch yield and dissolution efficiency (t[ 10 h) for all
experimental runs.
Formulation
batch
Theoretical weight
of batch (mg)
Batch
yield (%)
Dissolution
efficiency (% DE)
F1 850 81.76 66.35
F2 700 70.71 78.36
F3 850 74.70 61.26
F4 850 80 64.50
F5 1000 71.20 77.19
F6 1000 78.50 78.54
F7 700 83.28 69.4
F8 700 75.71 67.52
F9 1000 72 77.46Stability of MGL-PCL microspheres
The microspheres (F6) were subjected to accelerated
conditions (6 months of storage at a temperature of 40 2 C
and relative humidity of 75  5%) in a stability chamber
(Mack Pharmatech, India) and were analysed (at 0, 3 and 6
months) for their physical appearance, active pharmaceutical
ingredient (API) content and in vitro dissolution profile.27
The obtained results were compared against the optimized
formulation of the initial month as the reference.
Results
Microsphere yield
The microsphere yield for all of the experimental runs
(F1eF9) by the W1/O/W2 emulsification solvent-
evaporation technique was in the range of 70.71e83.28%
of the theoretical solid content utilized during the production
of microspheres, as shown in Table 2.
Statistical analysis of data for dependent variables Y1 and Y2
A total of 9 experimental runs were conducted for the
preparation of the microspheres, and the effects of indepen-
dent variables on dependent variables were investigated using
factorial design. The results obtained from all 9 experiments
are summarized in Table 2. Summary statistics for regression
analysis and ANOVA results for dependent variables Y1, Y2
are presented in Tables 3 and 4, respectively. A 32 full
factorial design suggested quadratic and linear mathematical
models for evaluating correlations between the formulation
variables and response (DL, EE), represented by following
equations:
DL¼ 11.80þ 4.37 X1þ 1.35 X2þ 1.02 X1 X2þ 1.76 X12þ 0.47 X22
EE ¼ 64.64 þ 15.96 X1 þ 0.59 X2
The regression coefficients (R2) of the above equations for
DL and EE were 0.9932 and 0.9696, respectively. A positive
value in the regression equation represents an effect that
favours the optimization (synergistic effect), while a negative
value indicates an inverse relationship (antagonistic effect)
between the factor and the response.25 A model p value less
than 0.05 indicates significant model terms. In the case of
response drug loading, X1, X2, X1 X2, and X1
2 were the
significant model terms, while for the response encapsulation
efficiency, the significant factor was X1, as shown in Table 4.
The model F-values for DL and EE were 87.89 and 95.59,
respectively, indicating the significance of each model. The
predicted r-squared of the model should be in the
reasonable agreement with the adjusted r-squared (difference
should be less than 0.2). The obtained values are shown in
Table 4 for the predicted r-squared, along with the adjusted
r-squared values of both responses. Adequate precision
measures the signal to noise ratio. A ratio greater than 4 is
desirable. The ratios of 25.463 (quadratic model for DL)
and 20.269 (linear model for EE) indicated an adequate
signal. The PRESS value is the measure of fit of the model
to the data points in the design, and it should be small
Table 3: Summary statistics for regression analysis of dependent variables Y1 and Y2.
Response Model SD R2 Adjusted R2 Predicted R2 PRESS Significance
Y1 [DL] Linear 1.40 0.9141 0.8854 0.7683 31.78 e
2FI 1.23 0.9446 0.9113 0.6929 42.12 e
Quadratic 0.56 0.9932 0.9819 0.9409 8.10 Suggested
Cubic 0.82 0.9950 0.9603 0.9560 124.04 e
Y2 [EE] Linear 2.83 0.9696 0.9594 0.9376 98.57 Suggested
2FI 3.10 0.9696 0.9513 0.9075 146.04 e
Quadratic 2.73 0.9859 0.9623 0.8375 256.50 e
Cubic 1.80 0.9979 0.9835 0.6246 592.68 e
DL is drug loading; EE is encapsulation efficiency.
Table 4: ANOVA results for measured responseY1 [DL] and Y2
[EE].
Source Sum of
squares
DF Mean
square
F value p Value
Prob > F
Model for Y1 136.23 5 27.25 87.89 0.0019
X1 114.49 1 114.49 369.32 0.0003
X2 10.88 1 10.88 35.10 0.0096
X1 X2 4.18 1 4.18 13.49 0.0349
X1
2 6.23 1 6.23 20.10 0.0207
X2
2 0.44 1 0.44 1.43 0.3184
Residual 0.93 3 0.31 e e
Model for Y2 1530.77 2 765.39 95.59 <0.0001
X1 1528.65 1 1528.65 190.91 <0.0001
X2 2.12 1 2.12 0.27 0.6249
Residual 48.04 6 8.01 e e
The model p value should be less than 0.05, indicating significant
model terms.
Table 5: Actual and predicted values obtained for responses.
Dependent
variables
Formulation
batches
Actual value Predicted
value
Residual
Y1 F1 13.28 13.62 0.34
F2 9.59 9.34 0.25
F3 10.71 10.92 0.21
F4 12.35 11.80 0.55
F5 16 16.03 0.034
F6 17.94 17.93 6.667E-003
F7 8.64 9.20 0.56
F8 10.3 9.99 0.31
F9 20.8 20.77 0.027
Y2 F1 61.83 65.23 3.40
F2 49.11 48.08 1.03
F3 61.50 64.04 2.54
F4 66.37 64.64 1.73
F5 78.62 80.01 1.39
F6 85.12 80.60 4.52
F7 48.23 48.68 0.45
F8 50.80 49.27 1.53
F9 80.17 81.20 1.03
Regression equation for fitted model (in terms of coded factors).
DL ¼ 11.80 þ 4.37 X1þ 1.35 X2þ 1.02 X1 X2þ 1.76 X12 þ 0.47
X2
2.
EE ¼ 64.64 þ 15.96 X1 þ 0.59 X2.
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observed PRESS values of 8.10 (quadratic model) and 98.57
(linear model) for responses Y1 and Y2, respectively. Table 5
shows the actual and predicted values, along with the
residual values (Figure 1) of both responses for all of the
formulation batches (F1eF9), with the minimum difference
between these values indicating that the suggested model for
each response was most suitable.
Drug loading (DL) and encapsulation efficiency (EE)
Table 1 summarizes that the percent DL varied from 8.64
(F7) to 20.8 (F9) for both factors. DL was in the ranges of
16e20.8% (polymer level at þ1) and 8.64e10.3% (polymer
level at 1). At the 1 level of surfactant concentration,
DL was obtained in the range of 9.58e16%, and the
highest DL (20.8%) was obtained at the þ1 level of
surfactant concentration. The percent EE was in the range
of 48.23 (F7) to 85.12% (F6). The percent EE was in the
ranges of 50.80, 66.37 and 85.12 at different (1, 0, þ1)
polymer levels. The highest EE (85.12%) was obtained at
the medium (0) level of surfactant concentration.
Fourier transform infrared spectroscopy (FTIR)
The FTIR spectra of MGL alone, PCL, and the
MGL-PCL microspheres of optimized formulation (F6) are
shown in Figure 4. The FTIR spectra of miglitol showedprominent peaks at 3390 cm1 and 1237e1162 cm1,
which were assigned to OeH stretching and bending
vibrations. Prominent peaks at 2853e2822 cm1 are
assigned to CeH stretching vibration. Peaks at 1454 and
1470 cm1 represent CeC stretching vibrations. CeN
stretching and CeO stretching bands were observed with
prominent peaks at 1262 cm1 and 1146e1017 cm1,
respectively. Symmetrical and asymmetrical eCH2
stretching bands were observed with peaks in the range of
2921e2861 cm1. The FTIR spectra of MGL-PCL micro-
spheres showed overlapping of the characteristic peaks at
3439 cm1, 2867 cm1, 1471 cm1, 1295 cm1, 1168e
1046 cm1, and 2946e2867 cm1, indicating the stable
nature of miglitol during the encapsulation process.
Surface morphology study by FESEM
Fig. 5-A shows representative FESEMmicrophotographs
of pure drug particles with smooth surfaces and irregular
shapes. The particle size (Fig. 5-B, C and D) of MGL-PCL
microspheres was in the range of 54.7e140 mm, and they
Figure 1: Residual plots of responses for drug loading (a) and encapsulation efficiency (b).
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structure.
Powder X-ray diffraction (XRD) study
Figure 6 shows the XRD patterns of pure drug (MGL),
PCL, and the MGL-PCL microspheres. Distinct peaks in
the XRD pattern of pure drug (MGL) were scattered at 2q
angles of 13.19, 14.96, 19.67, 22.30, 25.55 and 29.23,
indicated its crystalline form. Similarly, XRD of PCL
showed peaks from angles of 15e42, with highly intense
peaks at 20.45 and 22.85, indicating its semicrystalline
nature. The XRD peaks of pure MGL were less intense
and disappeared in the MGL-PCL microsphere formula-
tion. The intense XRD peaks of MGL-PCL microspheres
at angles of 20.48 and 22.48 suggested the presence of PCL
polymer.Figure 2: Two dimensional contour plot (a) and three dimensional re
drug loading.In vitro drug release and kinetics
In drug development, in vitro drug release study is an
important tool for determining drug-formulation interpreta-
tionquantitatively, andunder certain conditions, it can beused
as an alternate to bioequivalence studies. Figure 7 represents
the in vitro release of MGL from its marketed formulation
(Misobit50) and from MGL-PCL microspheres (F1eF9).
The dissolution efficiency for themicrosphere formulation was
in the range of 61.26e78.54% for 10 h of duration, as shown in
Table 2. The marketed tablet formulation (Misobit50)
released 99.03% of MGL within 40 min.
Stability of MGL-PCL microspheres
Under accelerated stability conditions, physicochemical
parameters, the appearance, drug content and in vitrosponse surface plot (b) showing effects of independent factors on
Figure 3: Two dimensional contour plot (a) and three dimensional response surface plot (b) showing effects of independent factors on
encapsulation efficiency.
Poly-e-caprolactone loaded miglitol microspheres370dissolution profile of an optimized formulation (F6), were
not altered significantly.
Discussion
MGL-PCL microspheres were successfully prepared by a
W1/O/W2 emulsification solvent-evaporation method with a
maximum production yield28 using a factorial design. The
selection of the internal and external emulsion phases was
based on the solubility of the MGL and polymer PCL. The
effects of independent variables in the factorial design for
all nine experimental runs indicated that low, medium and
high levels (1, 0, þ1) of polymer (PCL) and surfactantFigure 4: FTIR spectra of PCL (poly-e-caprolactone), MGL (pure
miglitol) and MS (microspheres).(PVA) concentrations had significant effects on response
DL (Y1) and EE (Y2). From the mathematical model
equation, it was observed that positive coefficients
increased the response with regard to the factor levels. The
main and interaction effects of independent variables were
studied by constructing 2D contour and 3D response
surface plots in Figures 2 and 3, respectively, which show
that DL and EE increased with an increase in the amount
of polymer, with a linear relationship between them, which
might have been due to the encapsulation of the
hydrophilic drug MGL using the hydrophobic PCL
polymer, enabling the restriction of drug molecules
entrapped inside the polymer layer and inhibiting them
from leaching out. An increase in surfactant (PVA)
concentration also increases the DL, but it represents a
nonlinear relationship, and the highest EE was observed
with a medium level of PVA and had no significant effect
on EE. To achieve patient compliance through the
reduction of multiple doses, the formulation should release
the drug in a sustained release pattern, which could be
fulfilled by the inclusion of biocompatible PCL polymer in
the microsphere formulation.
The microspheres were spherical in shape and were uni-
formly distributed as a result of complete evaporation of the
organic solvent (DCM) during the production process. The
drug-polymer compatibility was determined by the FTIR
(interaction) study. XRD study of the microspheres showed
that the polymer chains were more ordered when trans-
formed into the microsphere form, and drug was encapsu-
lated in the amorphous phase of the polymer.29
The initial drug release from microspheres could be due
to MGL adsorption on the microsphere surface, which re-
leases when it comes into contact with dissolution medium.
In cases of hydrophilic drugs, when they were encapsulated
using the W1/O/W2 double emulsion solvent evaporation
method with hydrophobic polymers, the drugs were
Figure 5: SEM micrographs: A e pure drug, B and C e size distribution of microspheres, D e microsphere surface structure.
M.R. Waghulde and J.B. Naik 371adsorbed near the surface of microspheres, showing a burst
effect.30,31 Moreover, release of the drug was further slowed
at a constant rate, indicating the potential hydrophobic
property of PCL polymer, which has the ability to release
the drug for extended periods of time. The lower release
rates from this polymer might be due to increased viscosity
in the organic phase, which undergoes solidification at a
moderate rate and forms a polymer coat around the
microsphere by preventing drug diffusion from the inner
phase to outer phase and shrinks the microsphere to form
its dense nature.31,32 The drug release profile revealed that,
despite the hydrophilic nature of MGL, there were greatFigure 6: XRD spectra of PCL (poly-e-caprolactone), MGL (pure
miglitol) and MS (microspheres).possible modification of the release profiles, which are
influenced by the polymer properties. The data obtained
from the drug release profile of the optimized batch (F6)
was fitted to different kinetic models, and the highest
value of R2 was 0.9901 for the zero order equation (drug
release from dosage forms that do not disaggregate and
release the drug at a constant rate). Further, the profile
was fitted in a KorsmeyerePeppas model to evaluate the
drug release from the polymeric system. The obtained n
value >1 indicated superb case II kinetics and showed
drug release related to diffusion and relaxation
mechanisms.Figure 7: Comparative drug release profile (CDP) of MF (mar-
keted formulation) and F1eF9 microsphere formulations.
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conditions because there were no significant changes in their
physicochemical properties, and sustained drug release was
observed.
Conclusion
The developedMGL-PCLmicrospheres had the potential
to reduce multiple doses and the adverse effects of a drug,
thus enhancing patient compliance. This study demonstrated
that a hydrophilic drug with a short elimination half-life
could be successfully encapsulated by the solvent evapora-
tion technique using a 32 factorial design as an effective RSM
tool. The prepared MGL microspheres were stable in nature
and could serve as a promising drug delivery system for
sustained release applications in the treatment of hyper-
glycaemia in patients with type-2 diabetes mellitus.
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